Citations

Clear

2303 citation(s) found for "Yu, Edward".

Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments
Lee, Scott D. , Shivashankar, Raina , Quirk, Daniel, Telliez, Jean-Baptiste, Andrews, John M., Marren, Amy , Loftus, Edward V. , Loftus, Edward V , Zhang, Haiying , Andrews, John, Mukherjee, Arnab

Mayo Clinic

Journal of Clinical Gastroenterology | August 2, 2020 | Volume: 55 | Issue: 3 | Pages: 195-206

10.1097/mcg.0000000000001396 | PMID 32740098 Get It

This article reviews therapeutic drug monitoring (TDM) use for current inflammatory bowel disease (IBD) treatments. IBD comprises Crohn’s disease and ulcerative colitis-chronic gastrointestinal inflammatory disorders. Treatment options for moderate to severe IBD include thiopurines; methotrexate; biologic agents targeting tumor necrosis factor, α4β7 integrin or interleukins 12 and 23; and Janus kinase inhibitors. TDM is recommended to guide treatment decisions for some of these agents. Published literature concerning TDM for IBD treatments was reviewed. S.D.L., R.S., and E.V.L. drew on their clinical experiences. Polymorphisms resulting in altered enzymatic activity inactivating thiopurine metabolites can lead to myelotoxicity and hepatotoxicity. Increased elimination of biologic agents can result from immunogenicity or higher disease activity, leading to low drug concentration and consequent nonresponse or loss of response. TDM may aid treatment and dose decisions for individual patients, based on monitoring metabolite levels for thiopurines, or serum drug trough concentration and antidrug antibody levels for biologic agents. Challenges remain around TDM implementation in IBD, including the lack of uniform assay methods and guidance for interpreting results. The Janus kinase inhibitor tofacitinib is not impacted by enzyme polymorphisms or disease activity, and is not expected to stimulate the formation of neutralizing antidrug antibodies. TDM is associated with implementation challenges, despite the recommendation of its use for guiding many IBD treatments. Newer small molecules with less susceptibility to patient variability factors may fulfill the unmet need of treatment options that do not require TDM, although further study is required to confirm this.
SIRT7‐mediated modulation of glutaminase 1 regulates TGF‐β‐induced pulmonary fibrosis
Choudhury, Malay , Yin, Xueqian , Schaefbauer, Kyle, Kang, Jeong Han , Leof, Edward B. , Schaefbauer, Kyle J., Kottom, Theodore J. , Roy, Bhaskar, Limper, Andrew H.

Mayo Clinic

The FASEB Journal | July 27, 2020 | Volume: 34 | Issue: 7 | Pages: 8920-8940

10.1096/fj.202000564r | PMID 32519817 Get It

Abstract In the current work we show that the profibrotic actions of TGF‐β are mediated, at least in part, through a metabolic maladaptation in glutamine metabolism and how the inhibition of glutaminase 1 (GLS1) reverses pulmonary fibrosis. GLS1 was found to be highly expressed in fibrotic vs normal lung fibroblasts and the expression of profibrotic targets, cell migration, and soft agar colony formation stimulated by TGF‐β required GLS1 activity. Moreover, knockdown of SMAD2 or SMAD3 as well as inhibition of PI3K, mTORC2, and PDGFR abrogated the induction of GLS1 by TGF‐β. We further demonstrated that the NAD‐dependent protein deacetylase, SIRT7, and the FOXO4 transcription factor acted as endogenous brakes for GLS1 expression, which are inhibited by TGF‐β. Lastly, administration of the GLS1 inhibitor CB‐839 attenuated bleomycin‐induced pulmonary fibrosis. Our study points to an exciting and unexplored connection between epigenetic and transcriptional processes that regulate glutamine metabolism and fibrotic development in a TGF‐β‐dependent manner.
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Bell, Erica H. , Shaw, Edward G. , Buckner, Jan C. , Barger, Geoffrey, Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , McElroy, Joseph P., Fleming, Jessica L. , Timmers, Cynthia , Salavaggione, Andrea L., Aldape, Kenneth , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Hunter, G.K., Crocker, Ian , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Zhang, Jianwen , Mehta, Minesh P. , Gilbert, Mark R. , Becker, Aline Paixão , Liu, Ziyan , Johnson, David, Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 29 | Pages: 3407-3417

10.1200/jco.19.02983 | PMID 32706640 Get It

PURPOSENRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375 ) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802.METHODSIDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates.RESULTSOf the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup.CONCLUSIONThis study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria
Chang, Alex R. , Wei, Guo , Boucher, Robert E. , Bhatt, Udayan, Cohen, Debbie L. , Drawz, Paul E. , Punzi, Henry , Haley, William E. , Hawfield, Amret , Horwitz, Edward , Morisky, Don, Rocco, Michael V. , Wall, Barry M. , Zias, Athena, Drawz, Paul , Freedman, Barry I , Haley, William E , Rocco, Michael V , Chang, Alexander R , Kramer, Holly , Grams, Morgan Erika , Berlowitz, Dan R. , Freedman, Barry I. , McLouth, Christopher J. , Papademetriou, Vasilios , Weiner, Daniel E. , Beddhu, Srinivasan

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 15, 2020 | Volume: 15 | Issue: 8 | Pages: 1121-1128

10.2215/cjn.12371019 | PMID 32669306 Get It

Background and objectives It is unclear whether the presence of albuminuria modifies the effects of intensive systolic BP control on risk of eGFR decline, cardiovascular events, or mortality. Design, setting, participants, & measurements The Systolic Blood Pressure Intervention Trial randomized nondiabetic adults ≥50 years of age at high cardiovascular risk to a systolic BP target of <120 or <140 mm Hg, measured by automated office BP. We compared the absolute risk differences and hazard ratios of ≥40% eGFR decline, the Systolic Blood Pressure Intervention Trial primary cardiovascular composite outcome, and all-cause death in those with or without baseline albuminuria (urine albumin-creatinine ratio ≥30 mg/g). Results Over a median follow-up of 3.1 years, 69 of 1723 (4%) participants with baseline albuminuria developed ≥40% eGFR decline compared with 61 of 7162 (1%) participants without albuminuria. Incidence rates of ≥40% eGFR decline were higher in participants with albuminuria (intensive, 1.74 per 100 person-years; standard, 1.17 per 100 person-years) than in participants without albuminuria (intensive, 0.48 per 100 person-years; standard, 0.11 per 100 person-years). Although effects of intensive BP lowering on ≥40% eGFR decline varied by albuminuria on the relative scale (hazard ratio, 1.48; 95% confidence interval, 0.91 to 2.39 for albumin-creatinine ratio ≥30 mg/g; hazard ratio, 4.55; 95% confidence interval, 2.37 to 8.75 for albumin-creatinine ratio <30 mg/g; P value for interaction <0.001), the absolute increase in ≥40% eGFR decline did not differ by baseline albuminuria (incidence difference, 0.38 events per 100 person-years for albumin-creatinine ratio ≥30 mg/g; incidence difference, 0.58 events per 100 person-years for albumin-creatinine ratio <30 mg/g; P value for interaction =0.60). Albuminuria did not significantly modify the beneficial effects of intensive systolic BP lowering on cardiovascular events or mortality evaluated on relative or absolute scales. Conclusions Albuminuria did not modify the absolute benefits and risks of intensive systolic BP lowering.
Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort
Gentry, Melanie T. , Syrjanen, Jeremy A. , Calvert, Kendrick J., Hughes, Samantha R., Brushaber, Danielle , Kremers, Walter K. , Bove, Jessica, Brannelly, Patrick , Coppola, Giovanni , Dheel, Christina, Dickinson, Susan, Faber, Kelley, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Deb, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Haley, Dana , Heuer, Hilary W. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kornak, John , Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Manoochehri, Masood , McGinnis, Scott, Miller, Bruce L. , Pearlman, Rodney , Petrucelli, Len, Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Sengdy, Pheth, Shaw, Leslie M. , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Boxer, Adam L. , Rosen, Howard J. , Calvert, Kendrick, Hughes, Samantha, Irwin, David J , Hsiung, Gink-Yuek , Miller, Bruce L , Kantarci, Kejal , Gentry, Melanie T , Kremers, Walter K , Lapid, Maria I. , Dickerson, Bradley, Fong, Jamie , Foroud, Tatiana , Gearhart, Deb, Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Knopman, David S. , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | July 13, 2020 | Volume: 16 | Issue: 8 | Pages: 1115-1124

10.1002/alz.12095 | PMID 32656921 Get It

AbstractObjectiveThe Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects evaluates familial frontotemporal lobar degeneration (FTLD) kindreds with MAPT, GRN, or C9orf72 mutations. Objectives were to examine whether health‐related quality of life (HRQoL) correlates with clinical symptoms and caregiver burden, and whether self‐rated and informant‐rated HRQoL would correlate with each other.MethodsIndividuals were classified using the Clinical Dementia Rating (CDR®) Scale plus National Alzheimer's Coordinating Center (NACC) FTLD. HRQoL was measured with DEMQOL and DEMQOL‐proxy; caregiver burden with the Zarit Burden Interview (ZBI). For analysis, Pearson correlations and weighted kappa statistics were calculated.ResultsThe cohort of 312 individuals included symptomatic and asymptomatic individuals. CDR® plus NACC FTLD was negatively correlated with DEMQOL (r = −0.20, P = .001), as were ZBI and DEMQOL (r = −0.22, P = .0009). There was fair agreement between subject and informant DEMQOL (κ = 0.36, P <.0001).ConclusionLower HRQoL was associated with higher cognitive/behavior impairment and higher caregiver burden. These findings demonstrate the negative impact of FTLD on individuals and caregivers.
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss, Francine M. , Wang, Victoria , Luger, Selina M. , Miller, Kenneth B., Stadtmauer, Edward A. , Avigan, David , Gascoyne, Randall D., Wagner, Henry, Strair, Roger , Sprague, Kellie , Litzow, Mark R. , Tallman, Martin S. , Horning, Sandra J., Foss, Francine , Jegede, Opeyemi A. , Whiteside, Theresa L , Arber, Daniel A. , Hogan, William J. , Lazarus, Hillard M.

Mayo Clinic

Transfusion | July 12, 2020 | Volume: 60 | Issue: 8 | Pages: 1867-1872

10.1111/trf.15798 | PMID 32654201 Get It

BackgroundExtracorporeal photopheresis (ECP) is an immunomodulatory cellular therapy which has been shown to induce a tolerogenic state in patients with acute and chronic graft‐vs‐host disease. ECOG‐ACRIN explored the activity of ECP as a part of a reduced intensity conditioning regimen in two multicenter trials in patients with MDS (E1902) and lymphomas (E1402). While both studies closed before completing accrual, we report results in 23 patients (17 MDS and 6 lymphoma).Study Design and MethodsPatients received 2 days of ECP followed by pentostatin 4 mg/m2 /day for two consecutive days, followed by 600 cGy of total body irradiation prior to stem cell infusion. Immunosuppression for aGVHD was infusional cyclosporine A or tacrolimus and methotrexate on day +1, +3, with mycophenolate mofetil starting on day 100 for chronic GVHD prophylaxis.ResultsAll patients engrafted, with median time to neutrophil and platelet engraftment of 15‐18 days and 10‐18 days respectively. Grade 3 or 4 aGVHD occurred in 13% and chronic extensive GVHD in 30%.ConclusionsThese studies demonstrate that ECP/pentostatin/TBI is well tolerated and associated with adequate engraftment of neutrophils and platelets in patients with lymphomas and MDS.
Comparing Clinical Characteristics and Outcomes in Patients with Non-Cystic Fibrosis Bronchiectasis with Non-Tuberculous Mycobacteria and/or Pseudomonas Aeruginosa Within the US Bronchiectasis and NTM Research Registry
Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , O'Donnell, Anne E , Choate, Radmila , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Metersky, Mark L. , Philley, Julie V. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

D104. PHENOTYPES, PROGNOSTIC TOOLS, AND ADJUNCT THERAPIES IN COUGH, CF AND NON-CF BRONCHIECTASIS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A7764-A7764

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7764 Get It

The Association of Chronic Macrolide Treatment and Incident Isolation of Non-Tuberculous Mycobacteria in Patients with Bronchiectasis
Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , Metersky, Mark L. , Choate, Radmila , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Philley, Julie V. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

D12. EPIDEMIOLOGY AND THERAPY IN CF AND NON-CF BRONCHIECTASIS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6200-A6200

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6200 Get It

Pulmonary Nontuberculous Mycobacterial Infection in Patients in the U.S. Bronchiectasis Research Registry: Use of Antibiotic Therapy and Adverse Events
Henkle, Emily , Aksamit, Timothy R. , Barker, Alan F., Eden, Edward , DiMango, Angela, Fennelly, Kevin P. , Johnson, Margaret M. , Knowles, Michael R. , McShane, Pamela J. , Noone, P.G., O’Donnell, Anne E., Olivier, K.N., Thomashow, Byron, Tino, Gregory , Winthrop, Kevin , O'Donnell, Anne E , Ku, Jennifer H , Metersky, Mark L. , Addrizzo‐Harris, Doreen , Basavaraj, Ashwin , Daley, Charles L. , Daniels, M. Leigh Anne , Choate, Radmila , Philley, Julie V. , Salathe, Matthias A. , Schmid, A.

Mayo Clinic

B106. BREAKTHROUGHS IN NTM DIAGNOSIS AND TREATMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A4358-A4358

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4358 Get It